Kiniksa Pharmaceuticals Ltd
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
KNSA$95.02-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income (Loss
(In thousands, except share and per share amounts)
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| · · Years Ended | |||||||||
| · · December 31, | |||||||||
| | 2023 | 2022 | 2021 | ||||||
| Revenue: | | | | | | | | | |
| Product revenue, net | | $233,176 | | $122,524 | | $38,544 | |||
| License and collaboration revenue | | | 37,083 | | | 97,656 | | | — |
| Total revenue | | 270,259 | | 220,180 | | 38,544 | |||
| Operating expenses: | | | | | |||||
| Cost of goods sold | | | 33,407 | | | 22,895 | | | 9,100 |
| Collaboration expenses | | | 56,524 | | | 24,071 | | | 835 |
| Research and development | | | 76,097 | | | 65,490 | | | 99,297 |
| Selling, general and administrative | | 129,427 | | | 97,951 | | | 85,948 | |
| Total operating expenses | | 295,455 | | 210,407 | | 195,180 | |||
| Income (loss) from operations | | (25,196) | | 9,773 | | (156,636) | |||
| Other income | | 8,544 | | | 1,253 | | | 97 | |
| Income (loss) before income taxes | | (16,652) | | 11,026 | | (156,539) | |||
| Benefit (provision) for income taxes | | 30,736 | | | 172,337 | | | (1,385) | |
| Net income (loss) | | $14,084 | | $183,363 | | $(157,924) | |||
| Net income (loss) per share attributable to common shareholders—basic | | $0.20 | | $2.64 | | $(2.30) | |||
| Net income (loss) per share attributable to common shareholders—diluted | | $0.20 | | $2.60 | | $(2.30) | |||
| Weighted average common shares outstanding—basic | | 70,058,952 | | | 69,382,275 | | | 68,576,810 | |
| Weighted average common shares outstanding—diluted | | | 71,922,915 | | | 70,421,322 | | | 68,576,810 |
| Comprehensive income (loss): | | | | | | | | | |
| Net income (loss) | | $14,084 | | $183,363 | | $(157,924) | |||
| Other comprehensive income (loss): | | | | | | | | | |
| Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax | | | (38) | | | 110 | | | (32) |
| Total other comprehensive income (loss) | | | (38) | | | 110 | | | (32) |
| Total comprehensive income (loss) | | $14,046 | | $183,473 | | $(157,956) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.